Get started
EGETIS THERAPEUTICS ABEE

EGETIS THERAPEUTICS AB

3.930SEKD
−0.120−2.96%
At close at Jun 5, 15:29 GMT
SEK
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

EGTX fundamentals

Key facts

Market capitalization‪1.41 B‬SEK
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−1.03SEK
Founded2006
Employees (FY)40
CEONicklas Westerholm
Websiteegetis.com
About

Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. Its projects include Emcitate for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The company was founded by Torsten Almén, Heidi Brurok, Louis J. Ignarro, Per Jynge, Jan Olof Gustav Karlsson, Ingemar Lundström, and Rob Towart in 2006 and is headquartered in Stockholm, Sweden.

Ownership
‪‪359.24 M‬‬
Free Float shares
‪‪224.87 M‬‬ (62.6%)
Closely held shares
‪‪134.37 M‬‬ (37.4%)
Free Float shares
‪‪224.87 M‬‬ (62.6%)
Closely held shares
‪‪134.37 M‬‬ (37.4%)
Capital structure
Market cap
‪‪1.41 B‬‬
Debt
‪‪106.50 M‬‬
Cash & equivalents
‪‪272.80 M‬‬
Enterprise value
‪‪1.25 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.41 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
31.09x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
31.09x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−1,050.00%‬
‪−900.00%‬
‪−750.00%‬
‪−600.00%‬
‪−450.00%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−120.00 M‬‬
‪‪−80.00 M‬‬
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−63.00 M‬‬
‪‪−42.00 M‬‬
‪‪−21.00 M‬‬
‪0.00‬
‪‪21.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Emcitate
By country
Period: 2024
Germany
Japan
France
Spain
Other Countries
Poland
Australia
United Kingdom
Italy
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬
Actual
Estimate
Earnings
Next:Aug 21, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.32‬
‪−0.24‬
‪−0.16‬
‪−0.08‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
EGTX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−120.00 M‬‬
‪0.00‬
‪‪120.00 M‬‬
‪‪240.00 M‬‬
‪‪360.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
‪‪440.00 M‬‬
Assets
Liabilities